Proposal for a new staging system of Sjögren’s syndrome using salivary gland SPECT/CT: comparison with Saxon test, MR sialography, and histopathological examination
Oral Radiology · 2026
DOI: 10.1007/s11282-025-00859-6 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Oral Radiology, 2026. Verfasst von Ai Shirai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative Diagnostic Imaging, Field of Oral and Maxillofacial Imaging and Histopathological Diagnostics, Course of Applied Science, The Nippon Den…. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Magnetic Resonance Imaging, Sialography, Single Photon Emission Computed Tomography Computed Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Sjögren's syndrome causes dryness of the eyes and mouth due to destruction of glandular tissue. Single-photon emission computed tomography/computed tomography (SPECT/CT) is used to evaluate salivary gland function. This study aimed to quantitatively evaluate the stage of Sjögren's syndrome using SPECT/CT maximum standardized uptake value (SUVmax) by comparing the SUVmax with the Saxon test, magnetic resonance (MR) sialography stage, and histopathological grade. METHODS: This study was conducted in 29 patients with Sjögren's syndrome who underwent the Saxon test, MR sialography, SPECT/CT, and histopathological examination. We compared the SPECT/CT SUVmax with the Saxon test, MR sialography stage, and histopathological grade to determine the stage of Sjögren's syndrome. We then calculated the cutoff value of SUVmax at pre-stimulation for the parotid glands in the early and late stages of Sjögren's syndrome. RESULTS: The SUVmax for > 2 g per 2 min by the Saxon test was higher than that for ≤ 2 g per 2 min. The SUVmax for MR sialography stages 0-1 was higher than that for stages 2-4. The SUVmax for histopathological grades 0-2 was higher than that for grades 3-4. The cutoff value for early and late Sjögren's syndrome was 20.55 (sensitivity, 0.85; specificity, 0.67). CONCLUSIONS: SPECT/CT is a highly suitable modality for quantitatively evaluating the stage of Sjögren's syndrome. Especially, the pre-stimulation SUVmax of the parotid glands serves as a valuable indicator for assessing Sjögren's syndrome stage and predicting prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Quantitative Diagnostic Imaging, Field of Oral and Maxillofacial Imaging and Histopathological Diagnostics, Course of Applied Science, The Nippon Dental University Graduate School of Life Dentistry at Niigata, 1-8 Hamau…
- Oral and Maxillofacial Surgery, Dry Mouth Clinic, The Nippon Dental University Niigata Hospital, 1-8 Hamaura-Cho, Chuo-Ku, Niigata, 951-8580, Japan.
- Department of Pathology, The Nippon Dental University School of Life Dentistry at Niigata, 1-8 Hamaura-Cho, Chuo-Ku, Niigata, 951-8580, Japan.
- Department of Oral and Maxillofacial Radiology, The Nippon Dental University School of Life Dentistry at Niigata, 1-8 Hamaura-Cho, Chuo-Ku, Niigata, 951-8580, Japan.
ORCID-Profile: Ai Shirai, Shuji Toya, Yasuo Okada, Ichiro Ogura
Zitieren
APA
Shirai, A., Toya, S., Okada, Y., & Ogura, I. (2026). Proposal for a new staging system of Sjögren’s syndrome using salivary gland SPECT/CT: comparison with Saxon test, MR sialography, and histopathological examination. Oral Radiology. https://doi.org/10.1007/s11282-025-00859-6
Vancouver
Shirai A, Toya S, Okada Y, Ogura I. Proposal for a new staging system of Sjögren’s syndrome using salivary gland SPECT/CT: comparison with Saxon test, MR sialography, and histopathological examination. Oral Radiology. 2026. doi:10.1007/s11282-025-00859-6
BibTeX
@article{Shirai2026,
author = {Shirai, Ai and Toya, Shuji and Okada, Yasuo and Ogura, Ichiro},
title = {Proposal for a new staging system of Sjögren’s syndrome using salivary gland SPECT/CT: comparison with Saxon test, MR sialography, and histopathological examination},
journal = {Oral Radiology},
year = {2026},
doi = {10.1007/s11282-025-00859-6}
}
EUVIMED